Search Results - "ENGEL, SAMUEL S."

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes by Green, Jennifer B, Bethel, M. Angelyn, Armstrong, Paul W, Buse, John B, Engel, Samuel S, Garg, Jyotsna, Josse, Robert, Kaufman, Keith D, Koglin, Joerg, Korn, Scott, Lachin, John M, McGuire, Darren K, Pencina, Michael J, Standl, Eberhard, Stein, Peter P, Suryawanshi, Shailaja, Van de Werf, Frans, Peterson, Eric D, Holman, Rury R

“…The addition of sitagliptin to usual care in patients with type 2 diabetes and cardiovascular disease was not associated with any change in the risk of major…”
Get full text

Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS by Cornel, Jan H, Bakris, George L, Stevens, Susanna R, Alvarsson, Michael, Bax, Willem A, Chuang, Lee-Ming, Engel, Samuel S, Lopes, Renato D, McGuire, Darren K, Riefflin, Axel, Rodbard, Helena Wachslicht, Sinay, Isaac, Tankova, Tsvetalina, Wainstein, Julio, Peterson, Eric D, Holman, Rury R

“…To evaluate chronic kidney disease (CKD) and cardiovascular outcomes in TECOS (Clinical trial reg. no. NCT00790205, clinicaltrials.gov) participants with type…”
Get full text

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus by Gantz, Ira, Chen, Menghui, Suryawanshi, Shailaja, Ntabadde, Catherine, Shah, Sukrut, O'Neill, Edward A, Engel, Samuel S, Kaufman, Keith D, Lai, Eseng

“…Omarigliptin is a once-weekly (q.w.) oral DPP-4 inhibitor that is approved for the treatment of patients with type 2 diabetes mellitus (T2DM) in Japan. To…”
Get full text

Glucagon receptor antagonism induces increased cholesterol absorption[S] by Guan, Hong-Ping, Yang, Xiaodong, Lu, Ku, Wang, Sheng-Ping, Castro-Perez, Jose M., Previs, Stephen, Wright, Michael, Shah, Vinit, Herath, Kithsiri, Xie, Dan, Szeto, Daphne, Forrest, Gail, Xiao, Jing Chen, Palyha, Oksana, Sun, Li-Ping, Andryuk, Paula J., Engel, Samuel S., Xiong, Yusheng, Lin, Songnian, Kelley, David E., Erion, Mark D., Davis, Harry R., Wang, Liangsu

“…Glucagon and insulin have opposing action in governing glucose homeostasis. In type 2 diabetes mellitus (T2DM), plasma glucagon is characteristically elevated,…”
Get full text

The Predictive Value of Time-Varying Noninvasive Scores on Long-Term Prognosis of NAFLD in South Korea by Chung, Sung Won, Park, Min Kyung, Zhang, Xiao, Wang, Tongtong, Jemielita, Thomas, Fernandes, Gail, Engel, Samuel S, Jang, Heejoon, Lee, Yun Bin, Cho, Eun Ju, Lee, Jeong-Hoon, Yu, Su Jong, Yoon, Jung-Hwan, Kim, Yoon Jun

“…This study aimed to examine whether repeated measurements on noninvasive fibrosis scores during follow-up improve long-term nonalcoholic fatty liver disease…”
Get full text

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies by Engel, Samuel S., Round, Elizabeth, Golm, Gregory T., Kaufman, Keith D., Goldstein, Barry J.

“…Introduction In a previous pooled analysis of 19 double-blind clinical studies conducted by Merck, which included data available as of July 2009 on 10,246…”
Get full text

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis by Engel, Samuel S, Golm, Gregory T, Shapiro, Deborah, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J

“…To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin…”
Get full text

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes by Williams-Herman, Debora, Engel, Samuel S, Round, Elizabeth, Johnson, Jeremy, Golm, Gregory T, Guo, Hua, Musser, Bret J, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J

“…In a previous pooled analysis of 12 double-blind clinical studies that included data on 6,139 patients with type 2 diabetes, treatment with sitagliptin, a…”
Get full text

Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S by Yu, Shengsheng, Fu, Alex Z, Qiu, Ying, Engel, Samuel S, Shankar, Ravi, Brodovicz, Kimberly G, Rajpathak, Swapnil, Radican, Larry

“…Abstract Aims Type 2 diabetes is a reported risk factor for more frequent and severe urinary tract infections (UTI). We sought to quantify the annual…”
Get full text

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials by Tajima, Naoko, Eiki, Jun‐ichi, Okamoto, Taro, Okuyama, Kotoba, Kawashima, Masaru, Engel, Samuel S

“…Aims/Introduction To explore the factors associated with the glucose‐lowering efficacy of sitagliptin treatment in Japanese patients with type 2 diabetes…”
Get full text

Efficacy and safety of metformin and sitagliptin‐based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study by Liu, Xiangyang, Wang, Li, Xing, Ying, Engel, Samuel S, Zeng, Longyi, Yao, Bin, Xu, Wen, Chen, Guojuan, Zhang, Ye, Zhang, Ruya, Liu, Shu, Weng, Jianping, Ji, Qiuhe

“…Aims/Introduction To assess the efficacy and safety of metformin/sitagliptin‐based dual/triple therapy in elderly Chinese patients with type 2 diabetes…”
Get full text

Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD by Akbari, Camilla, Dodd, Maja, Stål, Per, Nasr, Patrik, Ekstedt, Mattias, Kechagias, Stergios, Vessby, Johan, Rorsman, Fredrik, Zhang, Xiao, Wang, Tongtong, Jemielita, Thomas, Fernandes, Gail, Engel, Samuel S., Hagström, Hannes, Shang, Ying

“…Long-term studies of the prognosis of NAFLD are scarce. Here, we investigated the risk of major adverse liver outcomes (MALO) in a large cohort of patients…”
Get full text

Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus by Iglay, Kristy, Hannachi, Hakima, Joseph Howie, Patrick, Xu, Jinfei, Li, Xueying, Engel, Samuel S., Moore, Lori M., Rajpathak, Swapnil

“…Objective: Patients with type 2 diabetes (T2DM) often have multiple comorbidities which may impact the selection of antihyperglycemic therapies. The purpose of…”
Get full text

Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes by Shankar, R Ravi, Bao, Yuqian, Han, Ping, Hu, Ji, Ma, Jianhua, Peng, Yongde, Wu, Fan, Xu, Lei, Engel, Samuel S, Jia, Weiping

“…Introduction We evaluated the tolerability and efficacy of the addition of sitagliptin in Chinese patients with type 2 diabetes mellitus receiving stable…”
Get full text

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin by Lee, Seung-Hwan, Gantz, Ira, Round, Elizabeth, Latham, Melanie, O'Neill, Edward A, Ceesay, Paulette, Suryawanshi, Shailaja, Kaufman, Keith D, Engel, Samuel S, Lai, Eseng

“…Type 2 diabetes (T2D) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease…”
Get full text

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus by Ji, Linong, Han, Ping, Wang, Xiaoyue, Liu, Jingdong, Zheng, Shaoxiong, Jou, Ying‐Ming, O'Neill, Edward A, Golm, Gregory T, Engel, Samuel S, Kaufman, Keith D, Shankar, R Ravi

“…Introduction The results of a clinical trial to evaluate the efficacy and safety of initial combination therapy with sitagliptin and metformin in Chinese…”
Get full text

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial by Pratley, Richard E., Eldor, Roy, Raji, Annaswamy, Golm, Gregory, Huyck, Susan B., Qiu, Yanping, Sunga, Sheila, Johnson, Jeremy, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett

“…Aim To evaluate the efficacy and safety of ertugliflozin and sitagliptin co‐administration vs the individual agents in patients with type 2 diabetes who are…”
Get full text

Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database by Zhang, Qiaoyi, Rajagopalan, Srini, Mavros, Panagiotis, Engel, Samuel S., Davies, Michael J., Yin, Donald, Radican, Larry

“…Abstract Aims: This study examined the relationship of baseline characteristics and medication use in patients with type 2 diabetes who were prescribed…”
Get full text

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study by Dagogo‐Jack, Samuel, Liu, Jie, Eldor, Roy, Amorin, Guillermo, Johnson, Jeremy, Hille, Darcy, Liao, Yuqin, Huyck, Susan, Golm, Gregory, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett

“…Aims To assess ertugliflozin in patients with type 2 diabetes who are inadequately controlled by metformin and sitagliptin. Materials and Methods In this…”
Get full text

Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018 by Wang, Tongtong, Xi, Yuzhi, Raji, Annaswamy, Crutchlow, Michael, Fernandes, Gail, Engel, Samuel S, Zhang, Xiao

“…Data on the prevalence of non-alcoholic fatty liver disease (NAFLD) in subgroups of the United States (US) population are limited. This study was conducted to…”
Get full text